From radiolabeling and biodistribution to dosimetry and efficacy in diverse animal models, Perceptive Discovery delivers integrated, translatable data to accelerate your radiopharmaceutical pipeline from concept to clinic.
Perceptive Discovery offers comprehensive preclinical RLT services to support the discovery and development of radiopharmaceutical therapies. We work with biotech and pharmaceutical teams to design and execute custom studies that generate the translational data needed for IND submission and clinical advancement.
Our team of radiochemists, pharmacologists, cancer biologists, and imaging scientists bring deep expertise across a broad spectrum of isotopes, modalities, and therapeutic platforms. Whether developing a novel targeted radiotherapeutic or a companion diagnostic, we streamline radiolabeling, dosimetry, efficacy, and image analysis—all under one roof.
With over 900+ preclinical RLT studies supported, and 50+ IND-enabling dosimetry studies, we are a proven partner in bringing first-in-class radiopharmaceuticals to the clinic.
Perceptive delivers fully integrated preclinical RLT services encompassing radiolabeling, biodistribution, dosimetry, efficacy, and image analysis all supported by a deep bench-to-bedside workflow designed to generate translatable, IND-enabling data to accelerate radiopharmaceutical development.
We have supported 900+ preclinical RLT studies and 50+ dosimetry studies across species, all executed through our global network of six preclinical labs with integrated radiochemistry centers.
Our RLT program includes a full imaging suite (PET, SPECT, MRI, CT, IVIS, and cryofluorescence tomography [CFT]) and extensive experience with both alpha emitters (e.g., Ac-225, Pb-212, At-211) and beta emitters (e.g., Lu-177, Cu-67, Tb-161, I-131, Y-90).
We apply regulatory grade dosimetry, performing both direct and surrogate isotope imaging across multiple species (from rodents to non-human primates). These studies support dose estimation, organ toxicity prediction, and evaluation of radionuclide daughter translocation.
Perceptive’s RLT studies integrate longitudinal efficacy monitoring assessing tumor regression, survival outcomes, and hematology/clinical chemistry biomarkers while comparing candidates to standards of care. Results are correlated with dosimetry and biomarker data to inform translational decisions.
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
